Histogenics Corp (NASDAQ: HSGX) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Histogenics Corp to related businesses based on the strength of its risk, institutional ownership, valuation, analyst recommendations, earnings, profitability and dividends.
Risk and Volatility
Histogenics Corp has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Histogenics Corp’s peers have a beta of 0.90, suggesting that their average share price is 10% less volatile than the S&P 500.
Valuation & Earnings
This table compares Histogenics Corp and its peers top-line revenue, earnings per share (EPS) and valuation.
Histogenics Corp’s peers have higher revenue and earnings than Histogenics Corp. Histogenics Corp is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
50.1% of Histogenics Corp shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 23.8% of Histogenics Corp shares are owned by insiders. Comparatively, 11.9% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Histogenics Corp and its peers’ net margins, return on equity and return on assets.
This is a breakdown of current ratings and target prices for Histogenics Corp and its peers, as provided by MarketBeat.com.
Histogenics Corp currently has a consensus target price of $4.00, suggesting a potential upside of 84.33%. As a group, “Pharmaceuticals” companies have a potential upside of 28.30%. Given Histogenics Corp’s stronger consensus rating and higher possible upside, research analysts plainly believe Histogenics Corp is more favorable than its peers.
Histogenics Corp beats its peers on 7 of the 12 factors compared.
Histogenics Corp Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.